Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 5/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2137785 | 0.91 | HTT (0.47) | MAPTHTTNAMPTHDAC1HDAC8 | |
| SCHEMBL17240523 | 0.90 | RAB9A (0.46) | MAPTNAMPTMAPK14EPHX2NPC1 | |
| SCHEMBL17240458 | 0.88 | MAPK14 (0.43) | NAMPTHDAC1HDAC8HDAC6MAPK14 | |
| SCHEMBL2136407 | 0.87 | NAMPT (0.51) | NAMPTMAPK14HTR2C | |
| SCHEMBL2138839 | 0.82 | MAPT (0.48) | MAPTHTTNAMPTMAPK14SMN1; SMN2 | |
| SCHEMBL2133636 | 0.80 | RAB9A (0.56) | NAMPTMAPK14EPHX2NPC1RAB9A | |
| SCHEMBL2136526 | 0.76 | EPHX2 (0.52) | NAMPTMAPK14EPHX2NPC1RAB9A | |
| SCHEMBL2137173 | 0.76 | EPHX2 (0.54) | MAPTHTTHDAC8HDAC6EPHX2 | |
| SCHEMBL21921090 | 0.75 | SMN1; SMN2 (0.50) | MAPTNAMPTMAPK14EPHX2NPC1 | |
| SCHEMBL2137668 | 0.74 | NPC1 (0.54) | MAPK14EPHX2NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9522140-B2 | Aryl substituted carboxamide derivatives as calcium or sodium channel blockers | RAQUALIA PHARMA INC. (JP) | 2016-12-20 | — | — | US | disclosed |
| US-20150322052-A1 | ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS | RAQUALIA PHARMA INC (JP) | 2015-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322052-A1 | ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS | CACNA1I, CACNA1G, CACNA1H | MAPT 2659/4885HTT 633/4885NAMPT 1450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.